LRRC15 Recombinant Monoclonal Antibody

LRRC15, or leucine-rich repeat-containing protein 15, has emerged as a compelling target in cancer biology research due to its highly restricted expression pattern in normal tissues and marked upregulation in the tumor microenvironment, particularly in cancer-associated fibroblasts. Originally identified as a beta-amyloid-induced gene product, LRRC15 has gained significant attention as a potential therapeutic target and biomarker across multiple solid tumor types, making reliable detection tools essential for advancing this research.

This recombinant monoclonal antibody (clone 1D8) offers the consistency and reproducibility that demanding research applications require. Because it is produced from a defined genetic sequence rather than traditional hybridoma methods, you can expect uniform performance across lots, eliminating the variability that can compromise longitudinal studies or multi-site collaborations. The human IgG1 isotype format and affinity-chromatography purification ensure high purity suitable for sensitive detection methods.

Functional ELISA validation demonstrates robust binding activity across human, cynomolgus macaque, and mouse LRRC15 proteins, with EC50 values in the low nanogram-per-milliliter range. Notably, the antibody shows particularly high affinity for macaque and mouse orthologs, with EC50 values between 4.1 and 6.3 ng/mL, while human LRRC15 binding shows EC50 values of 12.2 to 15.8 ng/mL. This cross-species reactivity makes the antibody especially valuable for translational studies where preclinical models inform human disease research.

Whether you are investigating LRRC15 as a stromal marker in tumor biology, exploring its potential as an antibody-drug conjugate target, or characterizing its expression in inflammatory conditions, this antibody provides a reliable foundation for your quantitative binding studies.